Kodein Extractumpharma (Codeine Phosphate Hemihydrate)

• Kodein Extractumpharma, containing codeine phosphate hemihydrate, acts on the central nervous system to provide analgesia and cough suppression.
• Mild to moderate pain: reduces pain intensity and improves functional comfort.
• Cough: suppresses the cough reflex, providing relief from persistent coughing.
• Acute musculoskeletal pain: alleviates pain from strains, sprains, and minor injuries.
• Post‑operative pain: offers short‑term analgesia after surgical procedures.

• Codeine phosphate hemihydrate is a pro‑drug metabolized primarily by hepatic CYP2D6 enzymes to morphine, which then binds to μ‑opioid receptors in the central nervous system. Activation of these receptors inhibits ascending pain pathways and reduces the perception of pain, while also diminishing the cough reflex by acting on the medullary cough center. The combined effect results in analgesia and antitussive activity.

Codeine phosphate hemihydrate may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Nausea
• Constipation
• Drowsiness
• Dizziness
• Vomiting
• Dry mouth

Serious or Rare Side Effects

• Respiratory depression
• Dependence or addiction
• Severe allergic reaction (anaphylaxis)
• Hypotension
• Seizures

• When using Kodein Extractumpharma, several precautions should be observed to ensure safe therapy.
• Assess respiratory function: monitor for signs of respiratory depression, especially in patients with pulmonary disease.
• Monitor for dependence: use the lowest effective dose for the shortest duration.
• Use caution in hepatic impairment: dose adjustment may be required.
• Avoid concomitant CNS depressants: limit use with alcohol, benzodiazepines, or other opioids.
• Adjust dose in renal impairment: consider reduced dosing in severe renal dysfunction.
• Store at ambient temperature: keep in the original container, protect from moisture and heat.

Codeine phosphate hemihydrate can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• CNS depressants (e.g., benzodiazepines, alcohol, barbiturates): increased risk of profound sedation and respiratory depression.
• Monoamine oxidase inhibitors (MAOIs): may precipitate severe hypotension or serotonin syndrome.
• Other opioids: additive opioid effects leading to overdose.
• CYP2D6 inhibitors (e.g., quinidine, fluoxetine): reduce conversion to morphine, diminishing analgesic effect.
• Anticholinergic agents: may exacerbate constipation.

Moderate Interactions (Monitor Closely)

• Antihistamines: may increase sedation.
• Diuretics: may enhance hypotensive effect.
• SSRIs/SNRIs: potential for serotonin syndrome when combined with MAOIs.
• Antacids: may affect absorption minimally.
• Muscle relaxants: additive CNS depression.